[ad_1]
LONDON (Reuters) – Europe’s largest privately held biotech company, Germany-based BioNTech, has raised $270 million to support its work in developing personalized immunotherapies for cancer, ahead of an expected eventual stock market flotation.
[ad_2]
Source link
